原发性胆汁性胆管炎治疗市场：依治疗类型、通路、地区分类

Primary Biliary Cholangitis Treatment Market, By Treatment Type (Ursodeoxycholic Acid, Obeticholic Acid, and Others), By Distribution Channel, By Region

出版日期: 2023年12月18日 | 出版商:

Coherent Market Insights | 英文 128 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球原发性胆汁性胆管炎治疗市场预计在预测期（2023-2030年）将显着成长。预计将从 2023 年的 6.5 亿美元增至 2030 年的 11.741 亿美元，复合年增长率为 8.8%。

报告范围		报告详情
基准年	2022年	2023年市场规模	6.5亿美元
实际资料	2018-2021	预测期	2023-2030
预测期复合年增长率	8.80%	2030年市场规模预测	11.741 亿美元

图 1. 2023 年原发性胆汁性胆管炎治疗的全球市场占有率(%)（按地区）

原发性胆汁性胆管炎（PBC）是一种影响肝臟小胆管的慢性自体自体免疫肝病。随着疾病的进展，这些胆管（称为胆管）会结疤或受损，阻止胆汁在肝臟内自由流动，并随着时间的推移损害肝臟。 PBC的主要症状包括疲倦、搔痒和黄疸。如果不及时治疗，PBC 最终会导致肝硬化和肝功能衰竭。原发性胆汁性胆管炎治疗市场由针对该疾病发病机制和进展的各种途径的药物组成。熊去氧胆酸（UDCA）仍然是首选药物，但许多患者对其反应不佳或不不耐症。奥贝胆酸和纤维酸衍生物等二线治疗药物正在出现，以解决未满足的需求。

市场动态：

原发性胆汁性胆管炎治疗市场主要是由全球 PBC 盛行率上升所推动的。根据各种估计，全球 PBC 盛行率为每百万人 40 至 400 例。与传统治疗方法相比，具有更高疗效和更好耐受性的新型二线治疗方法的推出也推动了市场的发展。然而，新兴市场新药成本高、PBC 认知度低可能会抑制市场成长。具有新颖作用机制的管道药物的出现为该市场的参与者提供了机会。监管机构核准有效且安全的治疗方法将有助于满足难治性患者的需求。

本研究的主要特点

本报告对全球原发性胆汁性胆管炎治疗市场进行了详细分析，并列出了以2022年为基准年的预测期（2023-2030）的市场规模和復合年增长率。
它还强调了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
根据以下参数对全球原发性胆汁性胆管炎治疗市场的主要企业进行了分析，例如公司亮点、产品系列、主要亮点、绩效和策略。
本研究涵盖的主要公司有：Intercept Pharmaceuticals, Inc.、Highlight Therapeutics, SL、GSK plc.、百时美施贵宝公司、Enanta Pharmaceuticals、NW Biotherapeutics、Merck &Co Inc.、Ipsen Pharma、Johnson &Johnson、GENFIT、 Ironwood Pharmaceuticals , Inc.、Novartis AG、COUR Pharmaceuticals 和Kaken Pharmaceutical Co., Ltd.
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
全球原发性胆汁性胆管炎治疗市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球原发性胆汁性胆管炎治疗市场的各种策略矩阵，将有助于相关人员做出决策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 650 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	8.80%	2030 Value Projection:	US$ 1,174.1 Mn

Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that affects the small bile ducts in the liver. As the disease progresses, it causes scarring and injury to these bile ducts, known as bile ductules, which stops bile from flowing freely within the liver and damaging it over time. Some key symptoms of PBC include fatigue, itching, and jaundice. If left untreated, PBC can eventually result in cirrhosis or liver failure. The primary biliary cholangitis treatment market consists of drugs that target various pathways involved in the pathogenesis and progression of the disease. Ursodeoxycholic acid (UDCA) remains the first-line treatment but many patients do not adequately respond or are intolerant to it. Second-line treatments such as obeticholic acid and fibric acid derivatives are emerging to address the unmet needs.

Market Dynamics:

The primary biliary cholangitis treatment market is primarily driven by the rising prevalence of PBC globally. According to various estimates, the global prevalence of PBC ranges between 40 and 400 cases per million. The market is also propelled by the launch of novel second-line treatment options with higher efficacy and better tolerability profiles than conventional therapies. However, the market growth can be restrained by the high costs of newer drugs and lack of awareness about PBC in developing regions. Emergence of pipeline drugs with novel mechanisms of action represents an opportunity for players in this market. Regulatory approval of efficient and safe therapies can help address the needs of refractory patients.

Key Features of the Study:

This report provides an in-depth analysis of the global primary biliary cholangitis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global primary biliary cholangitis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Intercept Pharmaceuticals, Inc., Highlight Therapeutics, S.L., GSK plc., Bristol-Myers Squibb and Company, Enanta Pharmaceuticals, NW Biotherapeutics, Merck & Co Inc., Ipsen Pharma, Johnson & Johnson, GENFIT, Ironwood Pharmaceuticals, Inc., Novartis AG, COUR Pharmaceuticals, and Kaken Pharmaceutical Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global primary biliary cholangitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary biliary cholangitis treatment market

Detailed Segmentation:

By Treatment Type:
- Ursodeoxycholic Acid (UDCA)
- Obeticholic Acid (Ocaliva)
- Others (Fibrates (Tricor), etc.)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Intercept Pharmaceuticals, Inc.
- Highlight Therapeutics, S.L.
- GSK plc.
- Bristol-Myers Squibb and Company
- Enanta Pharmaceuticals
- NW Biotherapeutics
- Merck & Co Inc.
- Ipsen Pharma
- Johnson & Johnson
- GENFIT
- Ironwood Pharmaceuticals, Inc.
- Novartis AG
- COUR Pharmaceuticals
- Kaken Pharmaceutical Co., Ltd.

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Ursodeoxycholic Acid (UDCA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Obeticholic Acid (Ocaliva)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Others (Fibrates (Tricor), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Primary Biliary Cholangitis Treatment Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
India
China
Japan
Australia
ASEAN
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 - 2030, (US$ Mn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Intercept Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Highlight Therapeutics, S.L.
GSK plc.
Bristol-Myers Squibb and Company
Enanta Pharmaceuticals
NW Biotherapeutics
Merck & Co Inc.
Ipsen Pharma
Johnson & Johnson
GENFIT
Ironwood Pharmaceuticals, Inc.
Novartis AG
COUR Pharmaceuticals
Kaken Pharmaceutical Co., Ltd.
Analyst Views

9. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

原发性胆汁性胆管炎治疗市场：依治疗类型、通路、地区分类